XML 68 R58.htm IDEA: XBRL DOCUMENT v3.24.0.1
Collaboration Agreements, License Agreement and Revenues - Product Revenue, Net - Additional Information 1 (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Total revenue $ 147,752 $ 140,734 $ 235,309
Product Revenue, Net [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Total revenue 100,949 82,869 $ 47,638
Product Revenue, Net [Member] | Beijing Falikang Pharmaceutical Co Ltd      
Contract with Customer, Liability [Abstract]      
Reductions to gross accounts receivable 3,000 500  
China [Member]      
Contract with Customer, Liability [Abstract]      
Recognized as Revenue 500    
China [Member] | Product Revenue, Net [Member]      
Contract with Customer, Liability [Abstract]      
Contract with customer liability increase decrease in revenue due to changes to estimated variable consideration 2,900    
AstraZeneca Agreements [Member]      
Contract with Customer, Liability [Abstract]      
Deferred Revenue 179,851 175,646  
Recognized as Revenue 89,055    
AstraZeneca Agreements [Member] | China [Member]      
Contract with Customer, Liability [Abstract]      
Deferred Revenue 32,000    
Recognized as Revenue $ 3,500    
Constrained for Future Recognition [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Total revenue   $ 2,300